Finoriq research workspace
Benitec Biopharma Inc. (BNTC) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Benitec Biopharma Inc. (BNTC).
Company Snapshot
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
- Company
- Benitec Biopharma Inc. (BNTC)
- Ticker
- BNTC
- Market Cap
- $410.9M
- Latest Price
- $11.96
- Industry
- Biotech & Pharma
Benitec Biopharma Inc. (BNTC) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Benitec Biopharma Inc. (BNTC).
| Event | Form | Date |
|---|---|---|
| Election of Director On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma...Election of Director On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedm... | 8-K5.02 | 2026-05-29 |
| Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational UpdateBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update | 8-K2.02 | 2026-05-14 |
| Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational UpdateBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update | 8-K2.02 | 2026-02-12 |
| On December 1, 2025, Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders. The 2...On December 1, 2025, Benitec Biopharma Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The 2... | 8-K5.07 | 2025-12-02 |
| Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational UpdateBenitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update | 8-K2.02 | 2025-11-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.